InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,255.66
(
0.26%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biophud

Send PM Follow Ignore
Followers 0
Posts 394
Boards Moderated 0
Alias Born 08/12/2006

biophud

Re: DewDiligence post# 69107

Saturday, 12/06/2008 10:45:20 PM

Saturday, December 06, 2008 10:45:20 PM

Post# of 252302
Dew,

I have not looked at the data closely and I am not sure how much better Motavizumab is compared to Synagis. My feeing is that it is analogous to EPO/Aranesp. I think that MEDI's RSV vaccine has a better chance of being a game changer.

With regards to RSV, what is your read of ALNY's RNAi compound? The quantitative knock down of viral levels seems encouraging. Plus the compound is designed to treat active infection rather than be preventative.

Regards,

biophud
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up